Top Markets
#1 DogBull DogBull +109.06%
#2 MarsCoin MarsCoin +78.17%
#3 Siacoin Siacoin +59.69%
#4 ADO Protocol ADO Protocol +52.87%
#5 The Bitcoin Bull The Bitcoin Bull +26.43%
#6 Ontology Gas Ontology Gas +22.51%
#7 Apertum Apertum +15.00%
#8 Useless Coin Useless Coin +13.73%
#9 Uniswap Uniswap +13.08%
#10 UnifAI Network UnifAI Network +11.99%
Coin of the day
DogBull DogBull
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Lexeo Therapeutics, Inc. Common Stock Lexeo Therapeutics, Inc. Common Stock

Lexeo Therapeutics, Inc. Common Stock

LXEO
Classifica tra le azioni #15117
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical... Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.
Prezzo delle azioni
$4.74
Ultima sincronizzazione: 2026-08-31
Capitalizzazione di mercato
$372.19M
Variazione (1 giorno)
-2.47%
Variazione (1 anno)
-1.04%
Paese
US
Scambia Lexeo Therapeutics, Inc. Common Stock (LXEO)

Categoria

Healthcare
Ricavi di Lexeo Therapeutics, Inc. Common Stock (LXEO)
Ricavi nel Sep 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Lexeo Therapeutics, Inc. Common Stock, i ricavi attuali dell'azienda (TTM) sono pari a 0. Nel 2026, l'azienda ha registrato ricavi di 0 uguale a i ricavi dell'anno 2026, che erano pari a 0. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Lexeo Therapeutics, Inc. Common Stock da 2026 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
Non abbastanza dati per le date fornite.
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH